Pharmacotherapy of severe personality disorders: A critical review

Severe Personality Disorders

Volumn , Issue , 2007, Pages 137-163

  Rinne, Thomas ^a   Ingenhoven, Theo ^b  

^a Dutch Institute of Forensic Psychiatry and Psychology   (Netherlands)

^b Symfora Groep   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927016502     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511544439.010     Document Type: Chapter

References (45)

1. Akiskal, H. S. (1994). The temperamental borders of affective disorders. Acta Psychiatr Scand Suppl 379: 32-37.
2. Akiskal, H. S., Hantouche, E. G. and Allilaire, J. F. (2003). Bipolar II with and without cyclothymic temperament: “dark” and “sunny” expressions of soft bipolarity. J Affect Disord 73: 49-57.
3. American Psychiatric Association (2001). Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. Am J Psychiatry 158: 1-52.
4. Bogenschutz, M. P. and George, N. H. (2004). Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 65: 104-109.
5. Cloninger, C. R. (1987). A systematic method for clinical description and classification of personality variants. A proposal. Arch Gen Psychiatry 44(6): 573-588.
6. Cloninger, C. R., Svarkic, D. M. and Przybeck, T. R. (1993). A psychobiological model oftem- perament and character. Arch Gen Psychiatry 50(12): 975-990.
7. Coccaro, E. F. and Kavoussi, R. J. (1997). Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 54: 1081-1088.
8. Cornelius, J. R., Soloff, P. H., George, A., Ulrich, R. F. and Perel, J. M. (1993a). Haloperidol vs. phenelzine in continuation therapy of borderline disorder. Psychopharmacol Bull 29: 333-337.
9. Cornelius, J. R., Soloff, P. H., Perel, J. M. and Ulrich, R. F. (1993b). Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry 150: 1843-1848.
10. Cowdry, R. W. and Gardner, D. L. (1988). Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 45: 111-119.
11. De la Fuente, J. M. and Lotstra, F. (1994). A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 4: 479-486.
12. Farwell, W. R., Stump, T. E., Wang, J., Tafesse, E., L’ltalien, G. and Tierney, W. M. (2004). Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med 19: 1200-1205.
13. Gardner, D. L. and Cowdry, R. W. (1985). Alprazolam-induced dyscontrol in borderline personality disorder. Am J Psychiatry 142: 98-100.
14. Gitlin, M. J. (1993). Pharmacotherapy of personality disorders: conceptual framework and clinical strategies. J Clin Psychopharmacol 13: 343-353.
15. Goldberg, S. C., Schulz, S. C., Schulz, P. M., Resnick, R. J., Hamer, R. M. and Friedel, R. O. (1986). Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 43: 680-686.
16. Hollander, E., Allen, A., Lopez, R.P. et al. (2001).Apreliminarydouble-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 62: 199-203.
17. Hollander, E., Tracy, K. A., Swann, A. C. et al. (2003). Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 28: 1186-1197.
18. Hollander, E., Swann, A. C., Coccaro, E. F., Jiang, P. and Smith, T. B. (2005). Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 162: 621-624.
19. Knutson, B., Wolkowitz, O. M., Cole, S. W. et al. (1998). Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry 155: 373-379.
20. Koenigsberg, H. W., Reynolds, D., Goodman, M. et al. (2003). Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 64: 628-634.
21. Links, S., Steiner, M., Boiago, I. and Irwing, D. (1990). Lithium therapy for borderline patients: preliminary findings. J Pers Disord 4: 173-181.
22. Loewe, T. H., Nickel, M. K., Meuhlbacher, M. et al. (2006). Topiramate treatment for women with borderline personality disorder. J Clin Psychopharmacol 26: 61-66.
23. Montgomery, S. A. and Montgomery, D. (1982). Pharmacological prevention of suicidal behaviour. J Affect Disord 4: 291-298.
24. Montgomery, S. A., Roy, D. and Montgomery, D. B. (1983). The prevention of recurrent suicidal acts. Br J Clin Pharmacol 15(Suppl2): 183S-188S.
25. Nickel, M. K., Nickel, C., Mitterlehner, F. O. et al. (2004). Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry 65: 1515-1519.
26. Nickel, M. K., Nickel, C., Kaplan, P. et al. (2005). Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 57: 495-499.
27. Nickel, M. K., Loewe, T.H., Meuhlbacher, M. et al. (2006). Aripiprasole in the treatment of patients with borderline personality disorder; a double-controlled study. Am J Psychiatry 163: 833-838.
28. Parsons, B., Quitkin, F. M., McGrath, P. J. et al. (1989). Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 25:524-534.
29. Philipsen, A., Schmahl, C. and Lieb, K. (2004). Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry 37: 196-199.
30. Rinne, T., van den, B. W., Wouters, L. and van Dyck, R. (2002). SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 159: 2048-2054.
31. Salzman, C., Wolfson, A. N., Schatzberg, A. et al. (1995). Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 15: 23-29.
32. Siever, L. J. and Davis, K. L. (1991). A psychobiological perspective on the personality disorders. Am J Psychiatry 148: 1647-1658.
33. Simpson, E. B., Yen, S., Costello, E., et al. (2004). Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry 65: 379-385.
34. Soler, J., Pascual, J. C., Campins, M. J. et al. (2005). Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 162: 1221-1224.
35. Soloff, P. H. (1998). Symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bull Menninger Clin 62: 195-214.
36. Soloff, P. H. (2000). Psychopharmacology of borderline personality disorder. Psychiatr Clin North Am 23: 169-92, ix.
37. Soloff, P. H., George, A., Nathan, R. S., Schulz, P. M. and Perel, J. M. (1986a). Paradoxical effects of amitriptyline on borderline patients. Am J Psychiatry 143: 1603-1605.
38. Soloff, P. H., George, A., Nathan, R. S. etal. (1986b). Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry 43: 691-697.
39. Soloff, P. H., George, A., Nathan, S. et al. (1989). Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol 9: 238-246.
40. Soloff, P. H., Cornelius, J., George, A., Nathan, S., Perel, J. M. and Ulrich, R. F. (1993). Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 50: 377-385.
41. Trestman, R. L., Keefe, R. S., Mitropoulou, V. et al. (1995). Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatry Res 59:127-136.
42. Tritt, K., Nickel, C., Lahmann, C. et al. (2005). Lamotrigine treatment of aggression in female borderline-patients: a randomized, double blind, placebo-controlled study. J Psychopharmacol 19:287-291.
43. Zanarini, M. C. and Frankenburg, F. R. (2001). Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 62:849-854.
44. Zanarini, M. C. and Frankenburg, F. R. (2003). Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 160: 167-169.
45. Zanarini, M. C., Frankenburg, F. R. and Parachini, E. A. (2004). A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 65: 903-907.